We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF.
- Authors
Heistinger, Max; Stockenhuber, Felix; Schneider, Barbara; Pabinger, Ingrid; Brenner, Brigitte; Wagner, Brunhilde; Balcke, Peter; Lechner, Klaus; Kyrle, Paul A.
- Abstract
In a double-blind, randomized, placebo-controlled cross-over study, we investigated in seven patients with chronic renal failure the effect of conjugated estrogens (0.6 mg/kg/day for 5 days) on template bleeding time and on thromboxane A2 (TxA2), β-thromboglobulin (β-TG) and prostacyclin (PGI2) concentrations in blood emerging from the template bleeding time incisions. Administration of conjugated estrogens resulted in a significant shortening of the bleeding time in six out of seven patients with a maximum effect 7 and/or 14 days following treatment. Both TxA2 (measured as thromboxane B2, TxB2) and β-TG release in bleeding time blood were significantly higher following administration of conjugated estrogens as compared to placebo administration. No difference was seen in endothelial PGI2 (measured as 6-keto-prostaglandin F1α) formation when patients were treated with conjugated estrogens as compared to placebo administration over the 28 day observation period. We conclude that in patients with chronic renal failure, infusion of conjugated estrogens results in a significant shortening of the bleeding time together with an increase in platelet reactivity, as indicated by an increase of TxA2 and β-TG concentration in the microvasculature. No effect was seen on PGI2 production, thereby excluding a major effect on vascular prostaglandin metabolism.
- Subjects
CORTICOTROPIN releasing hormone; ESTROGEN; PROSTACYCLIN; CHRONIC kidney failure; THROMBOXANES; HEMORRHAGE
- Publication
Kidney International, 1990, Vol 38, Issue 6, p1181
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1038/ki.1990.331